CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 293.78 Billion KRW | -6.02% |
| 2022 | 312.59 Billion KRW | 4.71% |
| 2021 | 298.54 Billion KRW | 5.32% |
| 2020 | 283.46 Billion KRW | 21.48% |
| 2019 | 233.34 Billion KRW | 26.46% |
| 2018 | 184.51 Billion KRW | 2.81% |
| 2017 | 179.48 Billion KRW | -0.79% |
| 2016 | 180.91 Billion KRW | 6.02% |
| 2015 | 170.64 Billion KRW | 3.38% |
| 2014 | 165.06 Billion KRW | -5.94% |
| 2013 | 175.49 Billion KRW | -5.35% |
| 2012 | 185.42 Billion KRW | -6.49% |
| 2011 | 198.29 Billion KRW | 67.66% |
| 2010 | 118.26 Billion KRW | 6.3% |
| 2009 | 111.26 Billion KRW | 17.3% |
| 2008 | 94.85 Billion KRW | 11.65% |
| 2007 | 84.95 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 297.48 Billion KRW | -0.36% |
| 2024 Q1 | 298.55 Billion KRW | 1.62% |
| 2023 Q2 | 303.79 Billion KRW | -2.2% |
| 2023 Q3 | 320.17 Billion KRW | 5.39% |
| 2023 Q4 | 293.78 Billion KRW | -8.24% |
| 2023 FY | 293.78 Billion KRW | -6.02% |
| 2023 Q1 | 310.63 Billion KRW | -0.63% |
| 2022 Q3 | 310.78 Billion KRW | 4.2% |
| 2022 Q2 | 298.26 Billion KRW | 0.47% |
| 2022 FY | 312.59 Billion KRW | 4.71% |
| 2022 Q1 | 296.86 Billion KRW | -0.56% |
| 2022 Q4 | 312.59 Billion KRW | 0.58% |
| 2021 FY | 298.54 Billion KRW | 5.32% |
| 2021 Q2 | 294.65 Billion KRW | -0.13% |
| 2021 Q1 | 295.03 Billion KRW | 4.08% |
| 2021 Q4 | 298.54 Billion KRW | 1.0% |
| 2021 Q3 | 295.58 Billion KRW | 0.31% |
| 2020 Q4 | 283.46 Billion KRW | -0.93% |
| 2020 Q1 | 251.17 Billion KRW | 7.64% |
| 2020 Q2 | 267.05 Billion KRW | 6.32% |
| 2020 Q3 | 286.11 Billion KRW | 7.14% |
| 2020 FY | 283.46 Billion KRW | 21.48% |
| 2019 Q4 | 233.34 Billion KRW | 11.5% |
| 2019 FY | 233.34 Billion KRW | 26.46% |
| 2019 Q1 | 199.89 Billion KRW | 8.33% |
| 2019 Q2 | 208.26 Billion KRW | 4.18% |
| 2019 Q3 | 209.28 Billion KRW | 0.49% |
| 2018 FY | 184.51 Billion KRW | 2.81% |
| 2018 Q4 | 184.51 Billion KRW | -2.44% |
| 2018 Q3 | 189.14 Billion KRW | 2.15% |
| 2018 Q2 | 185.16 Billion KRW | 0.52% |
| 2018 Q1 | 184.2 Billion KRW | 2.63% |
| 2017 Q4 | 179.48 Billion KRW | -1.6% |
| 2017 FY | 179.48 Billion KRW | -0.79% |
| 2017 Q3 | 182.4 Billion KRW | -0.53% |
| 2017 Q2 | 183.37 Billion KRW | 1.08% |
| 2017 Q1 | 181.4 Billion KRW | 0.28% |
| 2016 Q2 | 175.41 Billion KRW | -1.72% |
| 2016 Q3 | 176.24 Billion KRW | 0.47% |
| 2016 FY | 180.91 Billion KRW | 6.02% |
| 2016 Q4 | 180.91 Billion KRW | 2.65% |
| 2016 Q1 | 178.48 Billion KRW | 4.59% |
| 2015 Q1 | 164.27 Billion KRW | -0.48% |
| 2015 Q3 | 172.4 Billion KRW | -1.26% |
| 2015 Q2 | 174.6 Billion KRW | 6.29% |
| 2015 Q4 | 170.64 Billion KRW | -1.02% |
| 2015 FY | 170.64 Billion KRW | 3.38% |
| 2014 FY | 165.06 Billion KRW | -5.94% |
| 2014 Q4 | 165.06 Billion KRW | 0.08% |
| 2014 Q3 | 164.94 Billion KRW | -2.45% |
| 2014 Q1 | 176.94 Billion KRW | 0.82% |
| 2014 Q2 | 169.08 Billion KRW | -4.44% |
| 2013 Q4 | 175.49 Billion KRW | 0.15% |
| 2013 FY | 175.49 Billion KRW | -5.35% |
| 2013 Q1 | 184.6 Billion KRW | -0.44% |
| 2013 Q2 | 177.55 Billion KRW | -3.82% |
| 2013 Q3 | 175.23 Billion KRW | -1.31% |
| 2012 Q2 | 180.44 Billion KRW | -2.48% |
| 2012 Q1 | 185.03 Billion KRW | -6.69% |
| 2012 Q3 | 189.14 Billion KRW | 4.82% |
| 2012 FY | 185.42 Billion KRW | -6.49% |
| 2012 Q4 | 185.42 Billion KRW | -1.97% |
| 2011 FY | 198.29 Billion KRW | 67.66% |
| 2011 Q4 | 198.29 Billion KRW | 2.35% |
| 2011 Q3 | 193.73 Billion KRW | 6.62% |
| 2011 Q2 | 181.7 Billion KRW | 3.63% |
| 2011 Q1 | 175.34 Billion KRW | 48.26% |
| 2010 Q1 | 119.25 Billion KRW | 7.18% |
| 2010 Q3 | 114.43 Billion KRW | -7.34% |
| 2010 Q4 | 118.26 Billion KRW | 3.35% |
| 2010 FY | 118.26 Billion KRW | 6.3% |
| 2010 Q2 | 123.49 Billion KRW | 3.56% |
| 2009 Q4 | 111.26 Billion KRW | 6.9% |
| 2009 FY | 111.26 Billion KRW | 17.3% |
| 2009 Q3 | 104.08 Billion KRW | -0.78% |
| 2009 Q2 | 104.89 Billion KRW | 0.07% |
| 2009 Q1 | 104.82 Billion KRW | 10.51% |
| 2008 Q1 | 89.16 Billion KRW | 4.96% |
| 2008 Q2 | 90.77 Billion KRW | 1.8% |
| 2008 Q3 | 88.46 Billion KRW | -2.54% |
| 2008 Q4 | 94.85 Billion KRW | 7.21% |
| 2008 FY | 94.85 Billion KRW | 11.65% |
| 2007 Q2 | 90.51 Billion KRW | -3.4% |
| 2007 FY | 84.95 Billion KRW | 0.0% |
| 2007 Q1 | 93.69 Billion KRW | 0.0% |
| 2007 Q4 | 84.95 Billion KRW | -6.98% |
| 2007 Q3 | 91.32 Billion KRW | 0.9% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -48.216% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 84.989% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 66.501% |
| HANDOK Inc. | 790.33 Billion KRW | 62.828% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -72.187% |
| Yuhan Corporation | 2814.07 Billion KRW | 89.56% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 77.663% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -214.279% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 84.95% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -22.54% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 37.346% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -155.525% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -24.196% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 15.673% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -48.216% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 29.916% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 41.217% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 50.155% |
| JW Holdings Corporation | 1176.26 Billion KRW | 75.024% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 51.938% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 79.052% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 54.455% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 16.081% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -90.719% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 20.744% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 39.715% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -48.216% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 72.749% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 83.405% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 54.455% |
| Yuhan Corporation | 2814.07 Billion KRW | 89.56% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 66.615% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -29.649% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 70.436% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 54.455% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 30.035% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 37.341% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 42.168% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 48.0% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 26.778% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 16.081% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 79.823% |
| Boryung Corporation | 922.36 Billion KRW | 68.149% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 33.602% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 37.346% |
| JW Lifescience Corporation | 255.83 Billion KRW | -14.833% |